The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The researchers also determined that the two most widely used IGRAs used for diagnosing the disease in developed countries are not accurate for active TB.
Researchers at the University of Cologne were able to show that the results of the 30-minute ICT test were concordant with standard methods, which can take up to 72 hours.
The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.